| Quarter | Score |
|---|---|
| 2022-Q3 | 65.7 |
| 2022-Q4 | 49.3 |
| 2023-Q1 | 49.1 |
| 2023-Q2 | 36.1 |
| 2023-Q3 | 48.7 |
| 2023-Q4 | 65.6 |
| 2024-Q1 | 70.3 |
| 2024-Q2 | 66.5 |
| 2024-Q3 | 57.4 |
| 2024-Q4 | 57.4 |
| 2025-Q1 | 58.6 |
| 2025-Q2 | 61.7 |
| 2025-Q3 | 81.2 |
| 2025-Q4 | 42.9 |
| 2026-Q1 | 75.7 |
| 2026-Q2 | 76.1 |
High consensus with active accumulation at an attractive valuation
Trading 19.8% below funds' estimated purchase price
2 of 18 tracked funds hold MNRO. Avg conviction: 0.5%. Net adding. First tracked at $17.00 (current -19.8% vs tracked).
Icahn Capital has 1.1% in this stock
Prices are approximate, based on 13F reported values (position value / shares), not actual cost basis. Data covers 17 tracked value-oriented funds. Holdings are reported quarterly with a ~45-day lag. Stock splits may affect share count comparisons. Returns are not annualized.
| Fund | % of Portfolio | Action |
|---|---|---|
| Icahn Capital | 1.1% | Hold |
| Citadel Advisors | 0.0% | Add |